drugset / Trial / NCT07369154
52-week Open Label Safety-Tolerability Study
NaSingle-groupOpen-labelTreatment
Summary
Phase 3, open label, multicenter study designed to assess the long term safety and tolerability of LB-102 for the treatment of adult patients with stable schizophrenia
Timeline
- Start
- 2026-04
- Primary completion
- 2028-12
- Completion
- 2029-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LB-102 | Small molecule | 50 mg | — |
| Subject | LB-102 | Small molecule | 100 mg | — |